Venus Remedies Limited has obtained regulatory approval for the sale of Paclitaxel 100mg/16.7ml and Zoledronic Acid 4mg in the Philippines, as well as marketing authorization for Bleomycin 15 IU in Saudi Arabia. These achievements reflect the company’s strategic efforts to expand its global presence and make a positive impact on healthcare.
The company remains committed to delivering pharmaceutical solutions that address critical medical needs and contribute to improved patient outcomes. Despite a slight decline in share prices, with shares standing at ₹386.25 on the BSE and dropping by 0.35% at the close of trading on Friday, Venus Remedies continues to focus on its mission to enhance healthcare worldwide.